Cargando…

PB2518: OPTIMIZING THE DETECTION OF 2,3- DIPHOSPHOGLYCERATE IN DRIED BLOOD SPOTS OF PATIENTS WITH SICKLE CELL DISEASE: UNTARGETED METABOLOMICS WITHIN THE GENOMED4ALL PROJECT

Detalles Bibliográficos
Autores principales:	van der Veen, Sigrid, van Dijk, Myrthe, Biemond, Bart, Cnossen, Marjon, Colombatti, Raffaella, Jans, Judith, Mañú Pereira, Maria Del Mar, Verhoeven, Nanda, Van Wijk, Richard, van Beers, Eduard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428823/ http://dx.doi.org/10.1097/01.HS9.0000976772.68469.f2

Ejemplares similares

P1500: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
por: van der Veen, S., et al.
Publicado: (2022)

P-023: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
por: S., VAN DER VEEN, et al.
Publicado: (2022)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
por: van Dijk, Myrthe, et al.
Publicado: (2023)

Untargeted metabolic profiling in dried blood spots identifies disease fingerprint for pyruvate kinase deficiency
por: van Dooijeweert, Birgit, et al.
Publicado: (2020)

PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
por: Traets, Marissa, et al.
Publicado: (2023)

Iron overload in patients with rare hereditary hemolytic anemia: Evidence‐based suggestion on whom and how to screen
por: van Straaten, Stephanie, et al.
Publicado: (2018)

Comment on: Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia
por: Sheehan, Vivien A., et al.
Publicado: (2022)

PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: M., VAN DIJK, et al.
Publicado: (2022)

Methodological aspects of the oxygenscan in sickle cell disease: A need for standardization
por: Rab, Minke A.E., et al.
Publicado: (2019)

PB2215: GLOBAL EPIDEMIOLOGY OF SICKLE CELL DISEASE: A SYSTEMATIC LITERATURE REVIEW
por: Colombatti, R., et al.
Publicado: (2022)

Incentive spirometry to prevent acute chest syndrome in adults with sickle cell disease; a randomized controlled trial
por: van Tuijn, Charlotte F.J., et al.
Publicado: (2020)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M. J., et al.
Publicado: (2022)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M.J., et al.
Publicado: (2023)

Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients
por: Rab, Minke A.E., et al.
Publicado: (2019)

PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Colombatti, Raffaella, et al.
Publicado: (2023)

2,3-Diphosphoglyceric Acid Changes in Uremia and During Hemodialysis
por: Kang, Sung Kyew, et al.
Publicado: (1986)

P-032: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE
por: A., IDRIZOVIC, et al.
Publicado: (2022)

Dried blood spot metabolomics reveals a metabolic fingerprint with diagnostic potential for Diamond Blackfan Anaemia
por: van Dooijeweert, Birgit, et al.
Publicado: (2021)

P1492: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
por: Rab, M., et al.
Publicado: (2022)

PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
por: M., RAB, et al.
Publicado: (2022)

P1478: INTEGRATIVE DIAGNOSIS OF SICKLE CELL DISEASE PATIENTS FOR PERSONALIZED MEDICINE
por: Idrizovic, A., et al.
Publicado: (2022)

Untargeted metabolic analysis in dried blood spots reveals metabolic signature in 22q11.2 deletion syndrome
por: Korteling, Dorinde, et al.
Publicado: (2022)

Challenges and Opportunities of Precision Medicine in Sickle Cell Disease: Novel European Approach by GenoMed4All Consortium and ERN-EuroBloodNet
por: Collado, Anna, et al.
Publicado: (2023)

BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
por: Atiq, Ferdows, et al.
Publicado: (2019)

Untargeted Metabolomics for Metabolic Diagnostic Screening with Automated Data Interpretation Using a Knowledge-Based Algorithm
por: Haijes, Hanneke A., et al.
Publicado: (2020)

Oxygen gradient ektacytometry‐derived biomarkers are associated with vaso‐occlusive crises and correlate with treatment response in sickle cell disease
por: Rab, Minke A. E., et al.
Publicado: (2020)

PB2224: IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM THE REAL WORLD ASSESSMENT SURVEY FOR SICKLE CELL DISEASE IN SAUDI (ROARS)
por: Ezzat, H., et al.
Publicado: (2022)

A Unique Monocyte Transcriptome Discriminates Sickle Cell Disease From Other Hereditary Hemolytic Anemias and Shows the Particular Importance of Lipid and Interferon Signaling
por: van Vuren, Annelies J., et al.
Publicado: (2021)

PB2528: THE IMPACT OF ZINC SUPPLEMENTATION ON HYPERBILIRUBINEMIA IN SICKLE CELL DISEASE
por: Al Farttoosi, Mohammed
Publicado: (2023)

PB2517: OSTEOMYELITIS IN CHILDREN WITH SICKLE CELL DISEASE: IS MRI PATHOGNOMONIC?
por: Al Lawati, Murtadha, et al.
Publicado: (2023)

PI-04: OXYGEN GRADIENT EKTACYTOMETRY-DERIVED BIOMARKERS ARE ASSOCIATED WITH THE OCCURRENCE OF ACUTE COMPLICATIONS IN SICKLE CELL DISEASE
por: M., RAB, et al.
Publicado: (2022)

PB2391: FREQUENCY OF IKZF3 MUTATION IN WALDENSTRÖM’S MACROGLOBULINEMIA
por: Taleb, Assia, et al.
Publicado: (2023)

PB2513: A RE-AUDIT OF PAIN MANAGEMENT IN SICKLE CELL PAIN CRISES
por: Zhou, Yuhui, et al.
Publicado: (2023)

PB2507: EFFECTS OF TSH ON HEMOGLOBIN S POLYMERIZATION, DEFORMABILITY AND ADHESION ON SICKLE CELL ERYTHROCYTES
por: Reis, Evelyn Mendonça, et al.
Publicado: (2023)

Metabolic Fingerprint in Hereditary Spherocytosis Correlates With Red Blood Cell Characteristics and Clinical Severity
por: van Dooijeweert, Birgit, et al.
Publicado: (2021)

PB2217: SICKLE CELL DISEASE IS A RISK FACTOR FOR THE PROGRESSION AND PROGNOSIS OF COVID-19
por: Goyal, V., et al.
Publicado: (2022)

PB2504: USE OF CONSUMER WEARABLES TO MONITOR AND PREDICT PAIN IN PATIENTS WITH SICKLE CELL DISEASE
por: Vuong, Caroline, et al.
Publicado: (2023)

PB2223: COST OF ILLNESS, EPIDEMIOLOGY AND HEALTHCARE RESOURCE UTILIZATION FOR SICKLE CELL DISEASE IN THE GULF “CESGU”
por: Soliman, D., et al.
Publicado: (2022)

PB2225: ENVIRONMENTAL MODIFIERS OF SEVERITY IN CHILDREN WITH SICKLE CELL DISEASE: A FEASIBILITY PILOT STUDY
por: Strouse, J., et al.
Publicado: (2022)

PB2505: THERAPEUTIC PHLEBOTOMY INSTANTLY AFFECTS BLOOD PARAMETERS AND VISCOCITY IN SICKLE CELL DISEASE PATIENTS
por: Jebali, Amna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_16v6ang8qi993atibo4qtf97vm